HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk
  • MJHLS Brand Logo

© 2022 MJH Life Sciences™ , NeurologyLive – Clinical Neurology News and Neurology Expert Insights. All rights reserved.

Marco Meglio

Marco Meglio, Associate Editor for NeurologyLive, has been with the team since October 2019. Follow him on Twitter @marcomeglio1 or email him at mmeglio@neurologylive.com​

Articles

Advancing the Treatment Paradigm for Myasthenia Gravis and Looking Toward the Future

October 05, 2022

Article

Nicholas Silvestri, MD, clinical professor at the University at Buffalo discussed topics related to the expansion of treatments for myasthenia gravis and the positive outlook of managing the disease.

NeuroVoices: Joe Kardine, MS, OTR, CBIS, on the Functionality and Applicability of the NuroSleeve Powered Arm Brace

October 05, 2022

Article

The clinical program manager at the Jefferson Center for Neurorestoration discussed a new approach to restoring arm function using a powered arm brace and muscle stimulation system.

Nerivio Remote Electrical Neuromodulation Could Serve as Alternate Treatment for Chronic Migraine

October 04, 2022

Article

No statistical differences were found between REN and the standard of care medications, in any of the effectiveness outcomes of pain single-treatment pain relief and pain freedom, nor in consistency of pain relief and pain freedom.

CNM-Au8 Shows Survival Benefit in HEALEY ALS Trial, But Fails to Meet End Points

October 03, 2022

Article

Despite not meeting its primary and secondary end points, CNM-Au8 will continue to be evaluated in an open-label extension in HEALEY ALS and could potentially be offered in an expanded access protocol program.

Trial Launched for Avidity’s AOC 1020 in Facioscapulohumeral Muscular Dystrophy

October 02, 2022

Article

Designed to treat the underlying cause of FSHD, AOC 1020 will be evaluated on safety, tolerability, pharmacokinetics, and pharmacodynamics in a cohort of 68 adults with the disease.

Reactions, Ramifications, and Forward Progress of Newly Approved AMX0035 for ALS

October 01, 2022

Article

Justin Klee and Josh Cohen, cofounders and cochief operating officers, Amylyx Pharmaceuticals, answered questions related to the new approval of AMX0035 for ALS and how it changes the treatment landscape going forward.

Night-Time Only Apomorphine Infusion Shows Benefit to Treating Parkinson Disease Insomnia

September 30, 2022

Article

Sleep changes experienced by patients on apomorphine infusion were indicated by scores on Insomnia Severity Index and Clinical Global Impression-Improvement Scale.

Open-Label Extension Data Highlight Tofersen’s Ability to Reduce SOD1 Protein in ALS

September 29, 2022

Article

Despite not improving clinical end points, treatment with tofersen was associated with reduced in the total concentration of SOD1 protein and neurofilament light chain, a marker of axonal injury.

AMX0035 Approved for the Treatment of ALS

September 29, 2022

Article

In additional data from CENTAUR, Amylyx touted the drug's ability to prolong tracheostomy-free and ventilation-free survival.

Verdiperstat Fails to Differentiate From Placebo in Critical HEALEY ALS Platform Trial

September 29, 2022

Article

After previously failing a phase 3 trial of patients with multiple system atrophy, verdiperstat continued to show an effect in patients with ALS that was similar to those on placebo.